Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Biesecker Lab/Clinical Genomics Section, |
RCV000172161 | SCV000051090 | uncertain significance | not provided | 2013-06-24 | criteria provided, single submitter | research | |
Laboratory for Molecular Medicine, |
RCV000040918 | SCV000064609 | uncertain significance | not specified | 2012-06-11 | criteria provided, single submitter | clinical testing | The Met31575Thr variant in TTN has not been reported in the literature nor previ ously identified by our laboratory. This variant has not been identified in larg e and broad populations by the NHLBI Exome Sequencing Project (http://evs.gs.was hington.edu/EVS). Computational analyses (biochemical amino acid properties, con servation, AlignGVGD, PolyPhen2, and SIFT) do not provide strong support for or against an impact to the protein. Additional information is needed to fully asse ss the clinical significance of the Met31575Thr variant. |
Gene |
RCV000172161 | SCV000237900 | likely benign | not provided | 2020-12-03 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 24503780, 23861362) |
Labcorp Genetics |
RCV000542073 | SCV000642518 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2017-02-10 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002390173 | SCV002672665 | uncertain significance | Cardiovascular phenotype | 2019-09-23 | criteria provided, single submitter | clinical testing | The p.M25078T variant (also known as c.75233T>C), located in coding exon 185 of the TTN gene, results from a T to C substitution at nucleotide position 75233. The methionine at codon 25078 is replaced by threonine, an amino acid with similar properties. This alteration (also described as NM_133378.4 c.94723T>C p.Met31575Thr) was reported in one individual with familial dilated cardiomyopathy (DCM) who also had variants in other cardiac-related genes (Pugh TJ et al. Genet. Med., 2014 Aug;16:601-8). This alteration has also been reported as a secondary cardiac variant in an exome cohort (Ng D et al. Circ Cardiovasc Genet, 2013 Aug;6:337-46). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV000172161 | SCV003827896 | uncertain significance | not provided | 2023-11-17 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000172161 | SCV005622079 | uncertain significance | not provided | 2024-05-23 | criteria provided, single submitter | clinical testing | Available data are insufficient to determine the clinical significance of the variant at this time. The frequency of this variant in the general population is uninformative in assessment of its pathogenicity. (http://gnomad.broadinstitute.org) This variant has been identified in at least one individual with autosomal dominant dilated cardiomyopathy. Polyphen and MutationTaster predict this amino acid change may be benign. |